ClinicalTrials.gg
CompletedNCT01554163Updated Feb 9, 2022Results posted

Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

A Phase 3 interventional study of Etoricoxib 30 mg and Celecoxib 200 mg in Osteoarthritis of the Knee, sponsored by Organon and Co. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The main purpose of this study is to establish that etoricoxib 30 mg is safe and not inferior to celecoxib 200 mg in the treatment of the signs and symptoms of osteoarthritis in Korean patients. Given that the efficacy of etoricoxib vs. placebo in the treatment of osteoarthritis has been established, and that prescription drugs, such as celecoxib, are available for the treatment of pain associated with osteoarthritis in Korea, it would be inappropriate to subject patients with a flare of osteoarthritic pain to the placebo treatment for 12 weeks, and thus the study is designed as an active-comparator study.

02

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • Osteoarthritis
  • Celecoxib
  • Etoricoxib
03

In context

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 239 is above the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is at least 40 years of age
  • Clinical diagnosis of osteoarthritis of the knee for greater than 6 months based on clinical and radiographic criteria
  • Female patients of must have a negative pregnancy test prior to study enrollment and must agree to remain abstinent, and use barrier, intramuscular, or implanted from Visit 1 until 28 days after the last dose of study medication.
  • Patient is of American Rheumatism Association (ARA) functional Class I, II, or III
  • Patient is willing to limit alcohol intake to 2 or less drinks per day during study and the follow-up period
  • Patient is willing to avoid unaccustomed physical activity for the duration of the study and follow-up period
  • With the exception of osteoarthritis, the patient is judged to be in good general health based on medical history, physical exam, and routine laboratory tests
  • Patient is able to read, understand and complete study questionnaires, including questions requiring a visual analog scale (VAS) response
  • Patient provides written for the trial
  • For prior non-steroidal anti-inflammatory drug (NSAID) users only, the patient has a history of positive therapeutic benefit with NSAIDs and has taken an NSAID prior to study enrollment and at a therapeutic dose level prior to study enrollment (Visit 1)
  • For prior NSAID users only, the patient assessment of Pain Walking on a Flat Surface (WOMAC Section A, Question1) at Visit 1 (prestudy) is less than 80 mm (100 mm VAS)
  • For prior NSAID users only, prior to randomization, and following discontinuation of NSAIDs during the specified patients must satisfy the following 3 flare criteria: Minimum of 40 mm on patient reported Pain Walking on a Flat Surface (WOMAC Section A, Question 1); Increase of 15 mm on patient reported Pain Walking on a Flat Surface (WOMAC Section A, Question 1) compared to prestudy baseline recorded at Visit 1; and A worsening in Investigator Global Assessment of Disease Status of at least 1 category on a 5 category scale compared to Visit 1 recording
  • For prior acetaminophen/paracetamol users only, patient has taken acetaminophen/paracetamol on a regular basis prior to study enrollment (Visit 1) and does not use NSAIDs for the treatment of osteoarthritis of the knee
  • For prior acetominophen/paracetamol users only, at both Visits 1 and 2, patients must satisfy all of the following 3 criteria: Minimum of 40 mm on patient reported Pain Walking on a Flat Surface (WOMAC Section A, Question 1); Investigator Global Assessment of Disease Status as fair, poor, or very poor; and Minimum of 40 mm on Patient Global Assessment of Disease Status (100 mm

VAS)

Exclusion criteria

Exclusion Criteria:

  • Patient has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy
  • Patient is legally incompetent (e.g., a minor or mentally incapacitated), or has active psychosis, or significant emotional problems at the time of the study which in the view of the investigator are sufficient to interfere with the conduct of the study
  • Patient has a history of gastric or biliary surgery (including gastric bypass surgery), or small intestine surgery that causes clinical malabsorption
  • Patient is allergic to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or celecoxib or any of their constituents
  • Patient is allergic to acetaminophen/paracetamol, or has (e.g., bronchoconstriction in association with nasal polyps) to aspirin or NSAIDs
  • Patient has an estimated is less than or equal to 30 ml/min
  • Patient has Class II-IV congestive heart failure
  • Patient has established ischemic heart disease, cerebrovascular disease, or peripheral vascular disease
  • Patient has uncontrolled hypertension with an diastolic exclusionary limit of > 90 mm Hg and a systolic exclusionary limit of > 140 mm Hg
  • Patient has moderate or severe hepatic insufficiency defined as score > 6
  • Patient has a history of neoplastic disease
  • Patient has a history of any illness, which in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient
  • Patient is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within the last 5 years) of drug or alcohol abuse or dependence
  • Patients considered morbidly obese with a (BMI) ≥ 35 kg/m\^2
  • Patient has new use (within 2 weeks of Visit 1 and during the entire duration of the study and follow-up period) of physical medicine modalities involving the study joint, including but not limited to: physical therapy, chiropractic interventions, acupuncture, Transcutaneous Electrical Nerve Stimulator (TENS), and ultrasound
  • Patient is expected to undergo surgery involving the study joint during the course of the study
  • Patients taking oral
  • Patients using intra-articular or hyaluronic acid injections to the study knee or other medication within 3 months of Visit 1
  • Patients using intravenous, intramuscular, or oral corticosteroids, intra-articular steroids or hyaluronic acid injections to any joint other than the study joint within 1 month of Visit 1
  • Patients using topical or systemic analgesic medications within 3 days of Visit 1 and throughout the duration of the study
  • Patients using non-study NSAID or cyclooxygenase 2 (COX-2) specific inhibitor during the study treatment period, with the exception of low-dose aspirin (≤ 325 mg/day)
  • Patients receiving a Chinese traditional arthritis treatment within 1 week of Visit 1
  • Patients with abnormalities on Visit 1 clinical examination or laboratory safety tests. Serum transaminases should be ≤ 150% of the
  • Patients currently participating in or has participated in a study with an

drug or device within 4 weeks of signing informed consent

  • Patients with an active peptic ulcer or a history of inflammatory bowel disease
  • Patients with a personal or family history of an inherited or acquired bleeding
  • Patients that are pregnant or breast-feeding, or expecting to conceive within the projected duration of the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Etoricoxib 30 mg

    Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.

    Drug: Etoricoxib 30 mg

  • Active comparator
    Celecoxib 200 mg

    Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.

    Drug: Celecoxib 200 mg

Interventions

  • Etoricoxib 30 mg tablet once daily for 12 weeks.

    Also known as: MK-0663, Arcoxia

  • Celecoxib 200 mg once daily for 12 weeks

    Also known as: Celebrex, Celebra

06

What researchers measure

Primary outcomes

  1. Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale

    The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The pain subscale rates participant pain during walking, using stairs, in bed, sitting or lying, and standing using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of pain and 100 is the highest level of pain. The pain subscale is calculated as the average of the responses to the 5 questions related to pain. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline, Week 2, Week 6, Week 12

Secondary outcomes

  1. Time-Weighted Mean Change From Baseline in the WOMAC Physical Function Subscale

    The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The physical function subscale rates participant pain during stair use, rising from sitting, standing, bending, walking, getting in/out of a car, shopping, putting on/taking off socks, rising from bed, lying in bed, getting in/out of the bath, sitting, getting on/off the toilet, heavy household duties, and light household duties using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of functioning and 100 is the highest level of functioning. The physical function subscale was calculated as the average of the responses to the 17 questions related to functional status. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline, Week 2, Week 6, Week 12

  2. Time-Weighted Mean Change From Baseline in the Participant Global Assessment of Disease Status

    The Participant Global Assessmet of Disease was a one item questionnaire that asked participants to answer the following question, "Considering all the ways your arthritis affects you, mark (X) on the scale for how well you are doing." The questionnaire employed a 0-100 mm visual analog scale (VAS) to record participant responses, with 0 representing the best possible assessment and 100 representing the worst possible assessment. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline, Week 2, Week 6, Week 12

  3. Time-Weighted Mean Response in the Participant Global Assessment of Response to Therapy

    Participants were asked to rate their global assessment of response to therapy on a Likert scale from 0 to 4, with 0 = excellent, 1 = good, 2 = fair, 3 = poor, 4 = none. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Week 2, Week 6, Week 12

  4. Time-Weighted Mean Change From Baseline in the Investigator Global Assessment of Disease Status

    Study investigators were asked to rate the global assessment of participant disease status on a Likert scale from 0 to 4, with 0 = very well, 1 = good, 2 = fair, 3 = poor and 4 = very poor. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline, Week 2, Week 6, Week 12

  5. Time-Weighted Mean Change From Baseline in the WOMAC Stiffness Subscale

    The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The stiffness subscale rates stiffness after first waking and later in the day using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of stiffness and 100 is the highest level of stiffness. The stiffness subscale is calculated as the average of the responses to the 2 questions related to stiffness. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline, Week 2, Week 6, Week 12

  6. Time-Weighted Mean Response on the Investigator Global Assessment of Response to Therapy

    Study investigators were asked to rate the global assessment of participant response to therapy on a Likert scale from 0 to 4, with 0 = excellent, 1 = good, 2 = fair, 3 = poor, 4 = none. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Week 6, Week 12

07

Results

Posted Dec 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneEtoricoxib 30 mgCelecoxib 200 mg
Started120119
Number treated119119
Completed112109
Not completed810
Withdrew: Adverse event30
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10
Withdrew: Non-compliance with study drug11
Withdrew: Protocol violation04
Withdrew: Withdrawal by subject15
Withdrew: Not treated10

Outcome measures

PrimaryTime-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale

The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The pain subscale rates participant pain during walking, using stairs, in bed, sitting or lying, and standing using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of pain and 100 is the highest level of pain. The pain subscale is calculated as the average of the responses to the 5 questions related to pain. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline, Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale-21.40 ± 1.35-19.76 ± 1.34
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.390 · Difference in ls mean change: -1.63 · 95% CI -5.37 to 2.10
SecondaryTime-Weighted Mean Change From Baseline in the WOMAC Physical Function Subscale

The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The physical function subscale rates participant pain during stair use, rising from sitting, standing, bending, walking, getting in/out of a car, shopping, putting on/taking off socks, rising from bed, lying in bed, getting in/out of the bath, sitting, getting on/off the toilet, heavy household duties, and light household duties using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of functioning and 100 is the highest level of functioning. The physical function subscale was calculated as the average of the responses to the 17 questions related to functional status. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline, Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Change From Baseline in the WOMAC Physical Function Subscale
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Change From Baseline in the WOMAC Physical Function Subscale-17.78 ± 1.28-16.46 ± 1.28
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.464 · Difference in ls mean change: -1.32 · 95% CI -4.88 to 2.23
SecondaryTime-Weighted Mean Change From Baseline in the Participant Global Assessment of Disease Status

The Participant Global Assessmet of Disease was a one item questionnaire that asked participants to answer the following question, "Considering all the ways your arthritis affects you, mark (X) on the scale for how well you are doing." The questionnaire employed a 0-100 mm visual analog scale (VAS) to record participant responses, with 0 representing the best possible assessment and 100 representing the worst possible assessment. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline, Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Change From Baseline in the Participant Global Assessment of Disease Status
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Change From Baseline in the Participant Global Assessment of Disease Status-24.71 ± 1.58-23.61 ± 1.58
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.624 · Difference in ls mean change: -1.09 · 95% CI -5.48 to 3.30
SecondaryTime-Weighted Mean Response in the Participant Global Assessment of Response to Therapy

Participants were asked to rate their global assessment of response to therapy on a Likert scale from 0 to 4, with 0 = excellent, 1 = good, 2 = fair, 3 = poor, 4 = none. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Response in the Participant Global Assessment of Response to Therapy
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Response in the Participant Global Assessment of Response to Therapy1.48 ± 0.061.56 ± 0.07
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.369 · Difference in ls mean change: -0.08 · 95% CI -0.26 to 0.10
SecondaryTime-Weighted Mean Change From Baseline in the Investigator Global Assessment of Disease Status

Study investigators were asked to rate the global assessment of participant disease status on a Likert scale from 0 to 4, with 0 = very well, 1 = good, 2 = fair, 3 = poor and 4 = very poor. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline, Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Change From Baseline in the Investigator Global Assessment of Disease Status
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Change From Baseline in the Investigator Global Assessment of Disease Status-1.71 ± 0.06-1.62 ± 0.06
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.294 · Difference in ls mean change: -0.09 · 95% CI -0.25 to 0.08
SecondaryTime-Weighted Mean Change From Baseline in the WOMAC Stiffness Subscale

The WOMAC osteoarthritis scale consists of 24 items in 3 subscales: pain, stiffness, and physical function. The stiffness subscale rates stiffness after first waking and later in the day using a visual analog scale (VAS) from 0-100mm where 0 is the best possible level of stiffness and 100 is the highest level of stiffness. The stiffness subscale is calculated as the average of the responses to the 2 questions related to stiffness. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline, Week 2, Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Change From Baseline in the WOMAC Stiffness Subscale
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Change From Baseline in the WOMAC Stiffness Subscale-18.41 ± 1.48-17.55 ± 1.48
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.679 · Difference in ls mean change: -0.86 · 95% CI -4.96 to 3.24
SecondaryTime-Weighted Mean Response on the Investigator Global Assessment of Response to Therapy

Study investigators were asked to rate the global assessment of participant response to therapy on a Likert scale from 0 to 4, with 0 = excellent, 1 = good, 2 = fair, 3 = poor, 4 = none. The calculation of the time-weighted average was done by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Week 6, Week 12
Reported as:
Least squares mean · Score on a Scale
Time-Weighted Mean Response on the Investigator Global Assessment of Response to Therapy
Score on a ScaleEtoricoxib 30 mgCelecoxib 200 mg
Time-Weighted Mean Response on the Investigator Global Assessment of Response to Therapy1.39 ± 0.071.49 ± 0.07
Statistical analysis
  • Etoricoxib 30 mg vs Celecoxib 200 mg · ANCOVA · p = 0.314 · Difference in ls mean change: -0.10 · 95% CI -0.30 to 0.10

Adverse events

Collected over Up to 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib 30 mg—0/119 (0%)12/119 (10.1%)
Celecoxib 200 mg—1/119 (0.8%)3/119 (2.5%)
Most frequent serious events
Most frequent serious events
EventEtoricoxib 30 mgCelecoxib 200 mg
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/119
Most frequent other events
Most frequent other events
EventEtoricoxib 30 mgCelecoxib 200 mg
ArthralgiaMusculoskeletal and connective tissue disorders12/1193/119

Baseline characteristics

Age, Customized
Age, Customized(Participants)Etoricoxib 30 mgCelecoxib 200 mgTotal
40 to 50 years41014
51 to 60 years414081
61 to 70 years464793
71 to 80 years271845
81 to 90 years246
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib 30 mgCelecoxib 200 mgTotal
Female110104214
Male101525
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yoo MC, Yoo WH, Kang SB, Park YW, Kim SS, Moon KH, Song YW, Min BW, Cho YJ, Moon SH, Bin SI, Baek HJ, Shim SC, Lee SW, Yoo DH, Mehta A, Skuban A, Cukrow DM, Vandormael K, Yan L. Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. Curr Med Res Opin. 2014 Dec;30(12):2399-408. doi: 10.1185/03007995.2014.955169. Epub 2014 Sep 3. PubMed 25133963 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2012
First posted
Mar 14, 2012
Start
Mar 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Dec 4, 2013
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01554163
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 14, 2012
Start date
Mar 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Dec 4, 2013
Last update
Feb 9, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion